CANDEL THERAPEUTICS INC

Explore how CEO Tak Paul Peter’s 10b5‑1 trades at Candel Therapeutics signal confidence, liquidity strategy, and future BLA milestones amid market volatility.

Insider sales at Candel Therapeutics reveal a routine liquidity move amid promising oncolytic viral therapy data; CYN‑01’s Phase III interim results will drive investor confidence.

Insider trades at Candel Therapeutics show routine selling and option buying, underscoring leadership confidence as the AURORA oncolytic virus trial drives future upside.

Insider buys 32,000 zero‑price options at Candel Therapeutics, signaling strong confidence ahead of clinical milestones and potential price gains.